Avanafil (Stendra) package insert; Sildenafil (Viagra) package insert; Vardenafil (Levitra) package insert; Tadalafil (Cialis) package insert; Yuan J, Zhang R, Yang Z. Comparative effectiveness
Herceptin. Package insert. Genentech Inc; 2024. 2. Herzuma. Package insert. Celltrion Inc; 2024. 3. Kanjinti. Package insert. Amgen Inc
Jardiance package insert, Steglatro package insert, Inpefa package insert] vs. either agent alone as initial therapy. In all of these trials
Tibsovo (ivosidenib) is an oral cancer agent that inhibits isocitrate dehydrogenase-1 (IDH1). Tibsovo is indicated for the treatment of adult patients with acute myeloid leukemia (AML), Tibsovo [package insert]. Boston, MA: Servier Pharmaceuticals, Inc.; October 2025. 2. NCCN Drugs Biologics Compendium
1Eliquis package insert 2 Pradaxa package insert 3Savaysa package insert 4 Xarelto package insert. CrCl should be based on the Cockcroft-Gault formula
The ivosidenib package insert indicates a warning for an increased risk of QTc interval prolongation in patients given this drug in combination with moderate or strong CYP3A4 inhibitors.
Package Insert. GlaxoSmithKline. 2024. 2. Ambisome. Package Insert. Gilead Sciences Inc. 2024. 3. Ampicillin. Package Insert. Pfizer. 2024. 4. Unasyn. Package
Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2025 2. Servier announces FDA approval of TIBSOVO (ivosidenib tablets) for the treatment of IDH1-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). Servier Pharmaceuticals LLC. Published Octo.
Enasidenib: Stein EM et al, Blood 2025; Fathi AT et al. JAMA Oncol. 2025; Norsworthy KJ et al. Clin Cancer Res. 2025; FDA package insert. Ivosidenib: DiNardo CD et al. NEJM 2025; Norsworthy KJ et al. Clin Cancer Res. 2025; FDA package insert. Olutasidenib: de Botton S et al. Blood Adv. 2025; FDA package insert.
I would like to know more about this package. ^.^